You are viewing the site in preview mode

Skip to content

Advertisement

  • Research article
  • Open Access
  • Open Peer Review

Subclinical tuberculosis among adults with HIV: clinical features and outcomes in a South African cohort

BMC Infectious Diseases201919:14

https://doi.org/10.1186/s12879-018-3614-7

  • Received: 23 January 2018
  • Accepted: 11 December 2018
  • Published:
Open Peer Review reports

Abstract

Background

Subclinical tuberculosis is an asymptomatic disease phase with important relevance to persons living with HIV. We describe the prevalence, clinical characteristics, and risk of mortality for HIV-infected adults with subclinical tuberculosis.

Methods

Untreated adults with HIV presenting for outpatient care in Durban, South Africa were screened for tuberculosis-related symptoms and had sputum tested by acid-fast bacilli smear and tuberculosis culture. Active tuberculosis and subclinical tuberculosis were defined as having any tuberculosis symptom or no tuberculosis symptoms with culture-positive sputum. We evaluated the association between tuberculosis disease category and 12-month survival using Cox regression, adjusting for age, sex, and CD4 count.

Results

Among 654 participants, 96 were diagnosed with active tuberculosis disease and 28 with subclinical disease. The median CD4 count was 68 (interquartile range 39–161) cells/mm3 in patients with active tuberculosis, 136 (72–312) cells/mm3 in patients with subclinical disease, and 249 (125–394) cells/mm3 in those without tuberculosis disease (P < 0.001). The proportion of smear positive cases did not differ significantly between the subclinical (29%) and active tuberculosis groups (14%, P 0.08). Risk of mortality was not increased in individuals with subclinical tuberculosis relative to no tuberculosis (adjusted hazard ratio 0.84, 95% confidence interval 0.26–2.73).

Conclusions

Nearly one-quarter of tuberculosis cases among HIV-infected adults were subclinical, which was characterized by an intermediate degree of immunosuppression. Although there was no significant difference in survival, anti-tuberculous treatment of subclinical cases was common.

Trial registration

Prospectively registered on ClinicalTrials.gov, NCT01188941 (August 26, 2010).

Keywords

  • Tuberculosis
  • Subclinical infections
  • HIV
  • AIDS-related opportunistic infections
  • Disease progression

Background

In 2016, over 10 million people worldwide developed active tuberculosis (TB) [1]. TB was the leading infectious disease cause of mortality as well as the leading cause of HIV-related mortality. Early diagnosis of highly contagious individuals as well as those at risk for progressing from latent infection to active disease may be critical for controlling the TB epidemic.

The traditional dichotomy of latent versus active TB has been more accurately modeled as a spectrum of infection whereby weakened host innate and acquired immune responses, as occur in HIV, allow mycobacterial replication [2, 3]. In the setting of increasing bacillary burden and host damage, clinical symptoms may develop. The preceding asymptomatic period during which viable M. tuberculosis can be detected in the host using existing microbiologic or radiologic tests has been described as subclinical TB. This disease state occurs on a continuum between latent and active disease [46].

The World Health Organization currently recommends all persons living with HIV (PLHIV) be screened for TB disease at each clinical encounter by assessing four TB-related symptoms: current cough, fever, night sweats, or weight loss [7]. Those who screen negative are eligible for isoniazid preventive therapy, while those who screen positive require further investigation for active TB disease. The overall sensitivity of this screen among PLHIV is estimated at 79% (95% confidence interval [CI] 58–91%) [8]. Persons with subclinical TB will be missed by this approach, potentially placing others at risk for infection and allowing disease to progress to active TB. In the HIV-coinfected population, progression may occur rapidly, thus raising the concern for higher risk of mortality among those with subclinical TB compared to latent TB [810]. It is not known how survival outcomes for subclinical disease compare with active disease. Given these potential implications, it is important to better characterize this asymptomatic disease state. We describe the prevalence, clinical and laboratory findings, and risk of death in a cohort of untreated (antiretroviral therapy [ART]-naïve) HIV-infected adults with subclinical TB in South Africa.

Methods

Study design

We enrolled untreated adults with HIV between October 2011 and January 2014 at four outpatient sites in KwaZulu-Natal, South Africa as previously described [11, 12]. Non-pregnant adults ≥18 years who had not received anti-tuberculous therapy (ATT) within three months were eligible for enrollment. No minors were included. The study was approved by the McCord Hospital Medical Research Ethics Committee, St. Mary’s Hospital Medical Research Ethics Committee, the University of KwaZulu-Natal Biomedical Research Ethics Committee, Partners Institutional Review Board, and the University of Washington Human Subjects Division. All participants provided written informed consent.

Procedures

At enrollment, study nurses recorded demographic and clinical information including TB-related symptoms: cough, fever, night sweats, and weight loss. Participants underwent CD4 T-cell count testing and provided a single expectorated sputum specimen; those unable to provide a sample underwent sputum induction with 3% hypertonic saline delivered by nebulizer. Specimens were transported daily to the TB laboratory at the University of KwaZulu-Natal for concentrated AFB smear and mycobacterial culture. Acid-fast bacilli (AFB) smear was performed using both Ziehl-Neelsen and auramine staining with fluorescence microscopy and graded according to standard criteria [13]. Culture was performed using both solid Middlebrook 7H11 agar and Bactec mycobacterial growth indicator tubes (MGIT) 960 system. Cases were considered culture positive based on identification of M. tuberculosis in either solid or liquid media. Participant urine samples were also tested for lipoarabinomannan (LAM) using the Determine™ TB LAM assay (Alere Inc.) [11]. LAM positive cases were designated as grade 1 or higher on using the manufacturer’s 5-grade reference card. All participants were offered treatment for HIV and TB according to South African Department of Health and WHO guidelines (ART initiated at CD4 ≤ 350 cells/mm3 for groups with TB disease and CD4 ≤ 200 cells/mm3 for groups without TB) [14, 15].

Outcomes were assessed 12 months after enrollment through review of clinical site TB registers and the Department of Health’s TB Control Programme. Information was recorded on TB treatment initiation, completion, default, failure, and death according to the South African Population Register [16].

Statistical analysis

Participants were categorized as having active TB disease, subclinical TB disease, or no microbiologic TB disease. Active TB cases were defined as having a positive M. tuberculosis culture in addition to the presence of at least one TB-related symptom. Subclinical TB cases were defined as having a positive M. tuberculosis culture but no TB-related symptoms. No microbiologic TB disease was defined as having no microbiologic evidence of M. tuberculosis by smear or culture and further subcategorized into those who were and were not treated empirically with multi-drug ATT at the discretion of the clinician, denoted as “no microbiologic TB/ATT” and “no microbiologic TB/no ATT” respectively.

Statistical methods used included Fisher’s exact test, one-way ANOVA, and Kruskal-Wallis test to compare baseline demographic, clinical, and laboratory characteristics between participants with active or subclinical TB and no microbiologic TB disease. Kaplan-Meier curves were used to display survival across TB diagnosis groups. We also evaluated the association between TB category and 12-month survival outcomes using Cox regression and adjusting for age, sex, and categorical CD4 count. We calculated both unadjusted and adjusted hazard rates and 95% CIs. In further analysis, we evaluated mortality outcomes in subgroups delineated by urine LAM status and ATT initiation. We also evaluated mortality according to baseline ART eligibility. The proportional hazards assumption was tested using log-log plots and time-varying predictors. Analyses were conducted in R [17].

Results

We enrolled 727 untreated PLHIV. After excluding 73 persons for whom mycobacterial culture and AFB smear data were missing, we included 654 participants for analysis. Mean age was 34 years, 348 (53%) were men, 160 (25%) currently smoked tobacco, and 53 (8%) reported prior treatment for TB (Table 1). At baseline, 243 (37%) had no TB-related symptoms, 139 (21%) had one symptom, 116 (18%) had two symptoms, 85 (13%) had three symptoms, and 71 (11%) had four symptoms. Median CD4 cell count was 206 (interquartile range [IQR] 81–349) cells/mm3. AFB smear was positive in 21 individuals (3%), mycobacterial culture was positive in 124 (19%), and urine LAM was positive in 99 (15%).
Table 1

Characteristics of adults with HIV stratified by tuberculosis status

 

All Individuals

N=654

Active TB

N=96

Subclinical TB

N=28

No Microbiologic TB/ATT1

N=40

No Microbiologic TB/No ATT

N=490

P Value

Demographics

 Mean age, years (SD)

34 (9)

35 (9)

33 (9)

36 (11)

34 (10)

0.55 2

 Men

348 (53%)

65 (68%)

14 (50%)

21 (53%)

248 (51%)

0.02

 Education: high school or higher

249 (38%)

34 (36%)

8 (29%)

12 (30%)

195 (40%)

0.39

 Marital status

  Never married

542 (83%)

83 (87%)

22 (79%)

32 (80%)

405 (83%)

0.53

  Currently married

89 (14%)

9 (9%)

6 (21%)

7 (18%)

67 (14%)

0.29

Clinical

 Current tobacco

160 (25%)

19 (20%)

7 (25%)

8 (20%)

126 (26%)

0.61

 Prior TB treatment

53 (8%)

8 (8%)

0

3 (8%)

42 (9%)

0.34

TB-related symptoms

 None

243 (37%)

0

28 (100%)

7 (18%)

208 (42%)

--

 Any 1 symptom

139 (21%)

23 (24%)

0

11 (28%)

105 (21%)

--

 Any 2 symptoms

116 (18%)

73 (76%)

0

22 (55%)

177 (36%)

--

 Any 3 symptoms

85 (13%)

53 (55%)

0

14 (35%)

89 (18%)

--

 All 4 symptoms

71 (11%)

23 (24%)

0

6 (15%)

42 (9%)

--

Median CD4 cell count (IQR), cells/mm3

206 (81 – 349)

68 (39 – 161)

136 (72 - 312)

90 (40 – 180)

249 (125 – 394)

<0.001

 <100

170 (30%)

55 (62%)

10 (37%)

21 (54%)

84 (20%)

<0.001

 100-200

108 (19%)

18 (20%)

8 (30%)

9 (23%)

73 (18%)

0.36

 >200

289 (51%)

16 (18%)

9 (33%)

9 (23%)

255 (62%)

<0.001

Eligible for ART initiation3

288 (51%)

79 (89%)

22 (81%)

30 (77%)

157 (38%)

<0.001

TB test results

 AFB smear positive

21 (3%)

13 (14%)

8 (29%)

0

0

0.08

  Low

2

0

2

   

  +

9

6

3

   

  ++

3

2

1

   

  +++

7

5

2

   

M. tuberculosis culture

124 (19%)

96 (100%)

28 (100%)

0

0

--

 positive

      

 Urine LAM positive

99 (15%)

35 (37%)

7 (25%)

9 (23%)

48 (10%)

<0.001

Abbreviations: AFB acid fast bacilli, ART antiretroviral therapy, ATT anti-tuberculous therapy, IQR interquartile range, LAM lipoarabinomannan, SD standard deviation, TB tuberculosis

1Empiric ATT

2P values compare all four subgroups with the exception of AFB smear positive and M. tuberculosis culture positive where active TB and subclinical TB only are compared

3ART was offered to all participants according to contemporaneous South African Department of Health and WHO guidelines and initiated at CD4 ≤350 cells/mm3 for groups with TB disease (included here as active and subclinical TB as well no microbiologic TB/ATT) and CD4 ≤200 cells/mm3 for no microbiologic TB/no ATT. CD4 data was available for 567 of 654 participants

Ninety six (15%) participants were diagnosed with active TB disease, 28 (4%) with subclinical TB disease, and 530 did not have microbiologic evidence of TB. Of those without proven disease, 40 (6%) were empirically treated with multi-drug ATT. There were no significant differences in mean age, education, marital status, baseline tobacco consumption, or prior TB treatment between the four subgroups. The active TB group had the highest proportion of men (68%, P 0.02).

Median CD4 count differed across groups: 68 (IQR 39–161) cells/mm3 in active TB, 136 (IQR 72–312) cells/mm3 in subclinical TB, 90 (IQR 40–180) cells/mm3 in no microbiologic TB/ATT and 249 (125–394) cells/mm3 in no microbiologic TB/no ATT, (P < 0.001). In addition to having a lower median CD4, the no microbiologic TB/ATT group had a higher burden of TB-related symptoms than the no microbiologic TB/no ATT group. According to baseline CD4 count and TB diagnosis, persons eligible for ART included 79 (89%) with active TB, 22 (81%) with subclinical TB, 30 (77%) with no microbiologic TB/ATT, and 157 (38%) with no microbiologic TB/no ATT (P < 0.001). Twenty-nine percent of individuals in the subclinical group were AFB smear positive compared to 14% in the active TB group (P 0.08). The proportion positive for urine LAM also differed across groups: 37% in active TB, 25% in subclinical TB, 23% in no microbiologic TB/ATT, and 10% in no microbiologic TB/no ATT (P < 0.001).

Vital status at 12 months was ascertained in all participants and death was documented in 25 (26%) of active TB, 3 (11%) of subclinical TB, 5 (13%) of no microbiologic TB/ATT, and 44 (9%) of no microbiologic TB/no ATT individuals (Table 2, Fig. 1). In univariate analysis, male sex, older age, and lower baseline CD4 count were associated with a higher hazard of death. Subclinical TB disease was associated with a similar hazard of death at 12 months compared to the reference no microbiologic TB/no ATT group (hazard ratio [HR] 1.22, 95% CI 0.38–3.93) while active TB disease was associated with a higher hazard of death compared to the reference group (HR 3.23, 95% CI 1.97–5.27). After adjusting for age, sex, and baseline CD4, there remained no evidence of a significant association between hazard of death comparing subclinical TB to reference (adjusted hazard ratio [aHR] 0.84, 95% CI 0.26–2.73), and the increased hazard of death comparing active TB to reference was attenuated and no longer significant (aHR 1.55, 95% CI 0.90–2.66). There was a nearly two-fold non-significant difference in 12-month survival comparing active to subclinical TB (aHR 1.84, 95% CI 0.55–6.17).
Table 2

Cox proportional hazards stratified by tuberculosis status

 

Active TB

N=96

Subclinical TB

N=28

No Microbiologic TB/ATT1

N=40

No Microbiologic TB/ No ATT

N=490

Death at 12 months

25 (26%)

3 (11%)

5 (13%)

44 (9%)

Unadjusted HR (95% CI)

3.23 (1.97, 5.27)

1.22 (0.38, 3.93)

1.40 (0.56, 3.54)

Reference

P value2

<0.001

0.74

0.47

 

Adjusted HR (95% CI)3

1.55 (0.90, 2.66)

0.84 (0.26, 2.73)

0.74 (0.29, 1.91)

--

P value2

0.11

0.77

0.53

 

Unadjusted HR (95% CI)

2.60 (0.78, 8.63)

Reference

  

P value4

0.12

   

Adjusted HR (95% CI)3

1.84 (0.55, 6.17)

--

  

P value4

0.32

   

Abbreviations: ATT anti-tuberculous therapy, CI confidence interval, HR hazard ratio, TB tuberculosis

1Empiric ATT treatment

2P values correspond to hazard ratios comparing survival to no microbiologic TB not treated reference group

3Adjusted for age, sex, CD4

4P values correspond to hazard ratios comparing survival to subclinical TB group

Fig. 1
Fig. 1

Kaplan Meier survival curves of adults with HIV stratified by tuberculosis status

Mortality outcomes were also examined in comparison to a reference group comprised of 442 individuals without microbiologic TB who also tested LAM negative and did not receive empiric ATT. The unadjusted hazard of death at 12 months comparing the subclinical TB group to this LAM negative reference was similar to earlier findings presented in Table 2 (HR 1.49, 95% CI 0.46–4.85) as was the hazard of death comparing the active TB group to the LAM negative reference (HR 3.93, 95% CI 2.34–6.61). After adjusting for age, sex, and baseline CD4, there remained no evidence of a significant association between hazard of death comparing subclinical TB to LAM negative reference (aHR 1.02, 95% CI 0.31–3.38). However, while the increased hazard of death comparing active TB to LAM negative reference was again attenuated, it remained significant (aHR 1.93, 95% CI 1.08–3.47). Finally, adjusted models stratified by LAM test result did not show a significant association between hazard of death comparing either subclinical or active TB groups to LAM negative reference.

Information on whether ATT was initiated was available for half of all TB cases: 15 of 28 individuals in the subclinical TB group and 48 of 96 individuals in the active TB group were known to start multi-drug ATT, while treatment initiation in the remaining individuals was not documented. Survival outcomes in these individuals were also examined in comparison to the no microbiologic TB/no ATT reference group. Treated subclinical TB disease was associated with a similar hazard of death at 12 months compared to the reference group (HR 0.73, 95% CI 0.10–5.33) while treated active TB disease was associated with a higher hazard of death compared to the reference group (HR 2.12, 95% CI 1.03–4.34). After adjusting for age, sex, and baseline CD4, there remained no evidence of a significant association between hazard of death comparing treated subclinical TB to reference (aHR 0.51, 95% CI 0.07–3.74), and there was no longer a significant difference in hazard of death comparing treated active TB to reference (aHR 0.88, 95% CI 0.41–1.88). There was a two-fold non-significant difference in 12-month survival comparing active to subclinical TB (aHR 2.01, 95% CI 0.24–16.80).

Discussion

The prevalence of subclinical TB in our population of untreated PLHIV in South Africa was high, accounting for 23% of all TB cases and 4% of the entire screened population. Subclinical TB cases presented with an intermediate degree of immunosuppression as reflected by a median CD4 count between those with active disease and no microbiologic TB/no ATT. We did not find evidence of reduced survival in adjusted models comparing subclinical or active TB to no microbiologic TB/no ATT individuals. This is one of the largest series of subclinical TB to date.

The high prevalence of subclinical TB among all screened participants in our study is consistent with other untreated HIV-infected populations. Subclinical disease has been reported to account for 6–52% of TB cases diagnosed by sputum culture [9, 10, 1829]. Despite this, it remains an underrecognized entity among PLHIV.

The degree of AFB smear positivity may have important implications for potential transmission [30], particularly as PLHIV with subclinical TB disease can progress to being symptomatic within several days to months [10, 24, 25]. Though we did not find a significant difference in the proportion of smear positive cases between subclinical and active TB groups, adequate power to detect such a difference was limited by sample size. Relative patterns in the literature have been variable, with one group describing greater smear positivity in subclinical disease [9] and others reporting greater bacillary burden and shorter time to culture positivity in active TB disease [10, 31]. The overall contribution of subclinical disease to TB transmission is not well understood.

The observed pattern of intermediate immunosuppression in subclinical TB is not consistently seen in all pre-ART cohorts. Some studies have reported similar CD4 values between groups [9] while others have described a notable difference [10].

With regard to survival outcomes, the study was not powered to detect a difference in adjusted survival hazards across groups. Baseline CD4 was a significant confounder; lower counts were strongly associated with increased hazard of death. Importantly, we did not fully measure ATT, ART, or treatment adherence, all of which impact survival. To address this issue, we performed subanalysis adjusting for ART eligibility according to TB diagnosis and baseline CD4 count. Persons with active TB, subclinical TB, or who were empirically treated for TB were considered eligible if their CD4 count was ≤350, while persons without microbiologic evidence of TB who did not receive ATT were considered eligible if their CD4 count was ≤200. Mortality outcomes did not differ significantly from main analysis. Furthermore, in subanalysis of subclinical and active TB groups documented to start ATT, mortality outcomes did not differ significantly from main analysis, though the adjusted hazard of death comparing active TB to reference was further attenuated albeit non-significant. A number of individuals with subclinical TB were started on ATT which was likely influenced by knowledge of culture results; in routine clinical practice where cultures are not obtained in the absence of symptoms, survival among subclinical TB patients may differ.

Diagnostic limitations of our study include collection and testing of only a single sputum sample per patient and lack of radiologic data. In addition, a number of adults without evidence of TB by sputum testing were urine LAM test positive; this finding could indicate extrapulmonary or undiagnosed pulmonary TB. To address potential misclassification, we performed subanalysis using a LAM negative no microbiologic TB reference group. Adjusted mortality outcomes were similar, though the increased hazard of death seen in the active TB group compared with reference remained significant.

Finally, since this study was conducted, HIV treatment guidelines have shifted to reflect the benefit of early ART initiation with regard to mortality, morbidity, and HIV transmission [3235]. With wider ART coverage, TB-related mortality has been reduced [36], though the impact on the epidemiology and natural history of subclinical TB remains unknown.

Conclusions

We report a high prevalence of subclinical TB in our cohort of HIV-infected adults in South Africa. These individuals were characterized by an intermediate degree of immunosuppression, and although no differences in mortality were observed, multi-drug ATT was commonly started in those with subclinical TB. Given the potential impact on morbidity and mortality, particularly among PLHIV, early identification of subclinical TB is critical.

Abbreviations

AFB: 

Acid-fast bacilli

aHR: 

adjusted hazard ratio

ART: 

antiretroviral therapy

ATT: 

anti-tuberculous therapy

CI: 

confidence interval

HR: 

hazard ratio

IQR: 

interquartile range

LAM: 

lipoarabinomannan

MGIT: 

mycobacterial growth indicator tubes

PLHIV: 

persons living with HIV

TB: 

tuberculosis

Declarations

Acknowledgements

We thank Katherine Thomas and Ting Hong for their valuable input with regard to data analysis.

Availability of data and material

The datasets analyzed for this study are available from the corresponding author on request.

Funding

The authors have no conflicts of interest to disclose. This work was supported by the Host Defense Training in Allergy and Infectious Diseases Grant [T32 AI007044] (KLB); the Harvard Global Health Institute (PKD); the Fogarty International Clinical Research Scholars and Fellows Program at Vanderbilt University [37] (PKD); the Infectious Disease Society of America Education & Research Foundation and National Foundation for Infectious Diseases (PKD); Massachusetts General Hospital Executive Committee on Research (PKD); the Program in AIDS Clinical Research Training Grant [T32 AI007433] (PKD); the Harvard University Center for AIDS Research [P30 AI060354] (PKD); the National Institute of Allergy and Infectious Diseases [K23 AI108293] (PKD) and [R01 AI058736] (KAF); and the National Institute of Mental Health [R01 MH090326] (IVB). The content is solely the responsibility of the authors and does not represent the official views of the National Institutes of Health or other funding agencies.

Authors’ contributions

KLB conducted the primary analysis and wrote the manuscript. IVB, SMC, DR, and KAF were involved in the design and conduction of the parent study as well as review of the manuscript. AW and PKD reviewed the data analysis and manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The study was approved by the McCord Hospital Medical Research Ethics Committee, St. Mary’s Hospital Medical Research Ethics Committee, the University of KwaZulu-Natal Biomedical Research Ethics Committee, Partners Institutional Review Board, and the University of Washington Human Subjects Division. All participants provided written informed consent.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Medicine, University of Washington, 1959 NE Pacific St., Box 356429, Seattle, WA 98195, USA
(2)
Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston University School of Public Health, Boston, USA
(3)
Boston University School of Public Health, Boston, USA
(4)
Department of Medicine, St. Mary’s Hospital, Durban, South Africa
(5)
Departments of Medicine, Epidemiology, and Laboratory Medicine, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, USA
(6)
Departments of Medicine, Global Health, and Epidemiology, University of Washington, Seattle, USA
(7)
Departments of Surgery and Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, USA

References

  1. World Health Organization. Global tuberculosis report. Geneva: 2017;1–147.Google Scholar
  2. Barry CE 3rd, Boshoff HI, Dartois V, Dick T, Ehrt S, Flynn J, et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol. 2009;7(12):845–55.View ArticleGoogle Scholar
  3. Lawn SD, Wood R, Wilkinson RJ. Changing concepts of "latent tuberculosis infection" in patients living with HIV infection. Clin Dev Immunol. 2011;2011.Google Scholar
  4. Achkar JM, Jenny-Avital ER. Incipient and subclinical tuberculosis: defining early disease states in the context of host immune response. J Infect Dis. 2011;204(Suppl 4):S1179–86.View ArticleGoogle Scholar
  5. Pai M, Behr MA, Dowdy D, Dheda K, Divangahi M, Boehme CC, et al. Tuberculosis. Nat Rev Dis Primers. 2016;2:16076.Google Scholar
  6. Drain PK, Bajema KL, Dowdy D, Dheda K, Naidoo K, Schumacher SG, et al. Incipient and subclinical tuberculosis: a clinical review of early stages and progression of infection. Clin Microbiol Rev. 2018;31(4):e00021-18.Google Scholar
  7. World Health Organization. Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. Geneva: 2011;1–39.Google Scholar
  8. Getahun H, Kittikraisak W, Heilig CM, Corbett EL, Ayles H, Cain KP, et al. Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med. 2011;8(1):e1000391.View ArticleGoogle Scholar
  9. Mtei L, Matee M, Herfort O, Bakari M, Horsburgh CR, Waddell R, et al. High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania. Clin Infect Dis. 2005;40(10):1500–7.View ArticleGoogle Scholar
  10. Oni T, Burke R, Tsekela R, Bangani N, Seldon R, Gideon HP, et al. High prevalence of subclinical tuberculosis in HIV-1-infected persons without advanced immunodeficiency: implications for TB screening. Thorax. 2011;66(8):669–73.View ArticleGoogle Scholar
  11. Drain PK, Losina E, Coleman SM, Giddy J, Ross D, Katz JN, et al. Rapid urine lipoarabinomannan assay as a clinic-based screening test for active tuberculosis at HIV diagnosis. BMC Pulm Med. 2016;16(1):147.View ArticleGoogle Scholar
  12. Bassett IV, Coleman SM, Giddy J, Bogart LM, Chaisson CE, Ross D, et al. Sizanani: a randomized trial of health system navigators to improve linkage to HIV and TB care in South Africa. J Acquir Immune Defic Syndr. 2016;73(2):154–60.View ArticleGoogle Scholar
  13. Lumb R, Van Deun A, Bastian I, Fitz-Gerald M. Laboratory diagnosis of tuberculosis by sputum microscopy: the handbook. Adelaide: SA Pathology, 2013;1–88.Google Scholar
  14. World Health Organization. Treatment of tuberculosis guidelines. Fourth ed. Geneva: 2010;1–160.Google Scholar
  15. Department of Health: Republic of South Africa. The South African antiretroviral treatment guidelines. Pretoria: 2010;1–21.Google Scholar
  16. Bassett IV, Coleman SM, Giddy J, Bogart LM, Chaisson CE, Ross D, et al. Barriers to care and 1-year mortality among newly diagnosed HIV-infected people in Durban, South Africa. J Acquir Immune Defic Syndr. 2017;74(4):432–8.View ArticleGoogle Scholar
  17. R Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2016.Google Scholar
  18. Bassett IV, Wang B, Chetty S, Giddy J, Losina E, Mazibuko M, et al. Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban. South Africa Clin Infect Dis. 2010;51(7):823–9.View ArticleGoogle Scholar
  19. Cain KP, McCarthy KD, Heilig CM, Monkongdee P, Tasaneeyapan T, Kanara N, et al. An algorithm for tuberculosis screening and diagnosis in people with HIV. N Engl J Med. 2010;362(8):707–16.View ArticleGoogle Scholar
  20. Henostroza G, Harris JB, Chitambi R, Siyambango M, Turnbull ER, Maggard KR, et al. High prevalence of tuberculosis in newly enrolled HIV patients in Zambia: need for enhanced screening approach. Int J Tuberc Lung Dis. 2016;20(8):1033–9.View ArticleGoogle Scholar
  21. Kerkhoff AD, Wood R, Lowe DM, Vogt M, Lawn SD. Blood neutrophil counts in HIV-infected patients with pulmonary tuberculosis: association with sputum mycobacterial load. PLoS One. 2013;8(7):e67956.View ArticleGoogle Scholar
  22. Kimerling ME, Schuchter J, Chanthol E, Kunthy T, Stuer F, Glaziou P, et al. Prevalence of pulmonary tuberculosis among HIV-infected persons in a home care program in Phnom Penh. Cambodia Int J Tuberc Lung Dis. 2002;6(11):988–94.PubMedGoogle Scholar
  23. Ahmad Khan F, Verkuijl S, Parrish A, Chikwava F, Ntumy R, El-Sadr W, et al. Performance of symptom-based tuberculosis screening among people living with HIV: not as great as hoped. AIDS. 2014;28(10):1463–72.View ArticleGoogle Scholar
  24. Lawn SD, Kerkhoff AD, Wood R. Progression of subclinical culture-positive tuberculosis to symptomatic disease in HIV-infected individuals. AIDS. 2011;25(17):2190–1.Google Scholar
  25. Lawn SD, Brooks SV, Kranzer K, Nicol MP, Whitelaw A, Vogt M, et al. Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med. 2011;8(7):e1001067.View ArticleGoogle Scholar
  26. Modi S, Cavanaugh JS, Shiraishi RW, Alexander HL, McCarthy KD, Burmen B, et al. Performance of clinical screening algorithms for tuberculosis intensified case finding among people living with HIV in Western Kenya. PLoS One. 2016;11(12):e0167685.View ArticleGoogle Scholar
  27. Rangaka MX, Wilkinson RJ, Glynn JR, Boulle A, van Cutsem G, Goliath R, et al. Effect of antiretroviral therapy on the diagnostic accuracy of symptom screening for intensified tuberculosis case finding in a south African HIV clinic. Clin Infect Dis. 2012;55(12):1698–706.View ArticleGoogle Scholar
  28. Shah S, Demissie M, Lambert L, Ahmed J, Leulseged S, Kebede T, et al. Intensified tuberculosis case finding among HIV-infected persons from a voluntary counseling and testing center in Addis Ababa. Ethiopia J Acquir Immune Defic Syndr. 2009;50(5):537–45.View ArticleGoogle Scholar
  29. Swindells S, Komarow L, Tripathy S, Cain KP, MacGregor RR, Achkar JM, et al. Screening for pulmonary tuberculosis in HIV-infected individuals: AIDS Clinical Trials Group protocol A5253. Int J Tuberc Lung Dis. 2013;17(4):532–9.View ArticleGoogle Scholar
  30. Nava-Aguilera E, Andersson N, Harris E, Mitchell S, Hamel C, Shea B, et al. Risk factors associated with recent transmission of tuberculosis: systematic review and meta-analysis. Int J Tuberc Lung Dis. 2009;13(1):17–26.PubMedGoogle Scholar
  31. Van't Hoog AH, Laserson KF, Githui WA, Meme HK, Agaya JA, Odeny LO, et al. High prevalence of pulmonary tuberculosis and inadequate case finding in rural western Kenya. Am J Respir Crit Care Med. 2011;183(9):1245–53.Google Scholar
  32. Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, Ouassa T, et al. A trial of early Antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373(9):808–22.View ArticleGoogle Scholar
  33. Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795–807.View ArticleGoogle Scholar
  34. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med. 2016;375(9):830–9.View ArticleGoogle Scholar
  35. Meintjes G, Moorhouse MA, Carmona S, Davies N, Dlamini S, van Vuuren C, et al. Adult antiretroviral therapy guidelines 2017. South Afr J HIV Med. 2017;18(1):776.View ArticleGoogle Scholar
  36. Kaplan R, Hermans S, Caldwell J, Jennings K, Bekker LG, Wood R. HIV and TB co-infection in the ART era: CD4 count distributions and TB case fatality in Cape Town. BMC Infect Dis. 2018;18(1):356.View ArticleGoogle Scholar
  37. Lawn SD, Kranzer K, Edwards DJ, McNally M, Bekker LG, Wood R. Tuberculosis during the first year of antiretroviral therapy in a south African cohort using an intensive pretreatment screening strategy. AIDS. 2010;24(9):1323–8.PubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2019

Advertisement